Review article: the epidemiology and prevention of gastric cancer
Top Cited Papers
- 10 June 2014
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 40 (3), 250-260
- https://doi.org/10.1111/apt.12814
Abstract
Gastric cancer can be divided into cardia and noncardia gastric adenocarcinoma (NCGA). Non cardia gastric cancer is a disease that has declined in global incidence but has remained as an extremely lethal cancer. To review recent advances in epidemiology and strategies in prevention of non cardia gastric cancer. A rapid literature search strategy was developed for all English language literature published before March 2013. The search was conducted using the electronic databases PubMed and EMBASE. The search strategy included the keywords 'stomach neoplasms', 'gastric cancer', 'epidemiology', 'risk factor', 'early detection of cancer', 'mass screening', 'cancer burden', 'prevention' and 'cost-effectiveness'. The search strategy was adjusted according to different requirements for each database. The specific search was also performed in cancer-related websites for country-specific information. The search was limited to past 10 years. Gastric cancer is the fifth most common cancer but the third leading cause of cancer death. The case fatality rate is 75%. Screening by radiological or endoscopic methods has limited success in prevention of gastric cancer. Helicobacter pylori has been identified as a carcinogen, accounting for 60-70% of gastric cancer globally and eradication is a potential preventive measure. A meta-analysis in 2009 demonstrated that individuals treated with H. pylori eradication therapy can reduce gastric cancer risk. The extended Shandong Intervention trial that lasted 14.3 years showed that H. pylori eradication therapy significantly reduced gastric cancer incidence by 39%. Consensus groups from Asia, Europe and Japan have recommended H. pylori eradication as primary prevention in high-risk areas. Following eradication therapy, endoscopic surveillance of pre-malignant lesions using enhanced imaging appears to be another promising preventive strategy. Gastric cancer remains a major diagnostic and therapeutic challenge. There is emerging evidence that H. pylori eradication in high gastric cancer regions can lead to a decline in the incidence of this highly lethal disease.This publication has 51 references indexed in Scilit:
- A new approach for elimination of gastric cancer deaths in JapanInternational Journal of Cancer, 2012
- Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)Endoscopy, 2011
- Age-Specific Trends in Incidence of Noncardia Gastric Cancer in US AdultsJama-Journal Of The American Medical Association, 2010
- Narrow Band Imaging for the Detection of Gastric Intestinal Metaplasia and Dysplasia During Surveillance EndoscopyDigestive Diseases and Sciences, 2010
- EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentaryEuropean Journal of Cancer, 2009
- Exploring the cost‐effectiveness ofHelicobacter pyloriscreening to prevent gastric cancer in China in anticipation of clinical trial resultsInternational Journal of Cancer, 2008
- Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trialThe Lancet, 2008
- Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysisBritish Journal of Cancer, 2008
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006
- Interleukin-1 polymorphisms associated with increased risk of gastric cancerNature, 2000